3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Hematologic Neoplasms
3
Neoplasms, Plasma Cell
2
Lymphoma
2
Leukemia
2
Infections
2
Waldenstrom Macroglobulinemia
1
Urinary Tract Infections
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Recurrence
1
Pulmonary Arterial Hypertension
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumonia
1
Pancreatic Neoplasms
1
Pancreatic Diseases
1
Pain
1
Other Infectious Diseases
1
Neutropenia
1
Neoplasms
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Migraine Disorders
1
Interventions
pegfilgrastim
26
Filgrastim
24
Cyclophosphamide
8
Docetaxel
7
Etoposide
6
pegylated granulocyte colony-stimulating factor
5
Cytarabine
5
eflapegrastim
4
Granulocyte Colony-Stimulating Factor
4
Leucovorin
3
Fluorouracil
3
Doxorubicin
3
Cyclosporine
3
Cefepime
3
Caspofungin
3
Carboplatin
3
liposomal amphotericin B
2
Vincristine
2
Vancomycin
2
Topotecan
2
Methylprednisolone
2
Methotrexate
2
Itraconazole
2
Irinotecan
2
Ifosfamide
2
Idarubicin
2
Fluconazole
2
Daunorubicin
2
Cisplatin
2
Amikacin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neutropenia
×
Piperacillin, Tazobactam Drug Combination
×
Clear all
NCT01431326
2023-09-06
PTN_POPS
Duke University
Completed
3,520 enrolled